TQ-B3525

DRUG6 trials

Sponsors

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Conditions

Chronic Kidney DiseasesHR-positive, HER2-negative and PIK3CA Mutation Advanced Breast CancerMagnetic Resonance ImagingPeripheral T-cell LymphomaRelapsed / Refractory Follicular LymphomaRelapsed / Refractory Mantle Cell Lymphoma (MCL)Relapsed or Refractory Lymphoma or Advanced Cancer

Phase 1

A Study of TQ-B3525 on Tolerance and Pharmacokinetics

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Relapsed or Refractory Lymphoma or Advanced Cancer

Start: 2018-06-20End: 2024-08-31Target: 60Updated: 2023-04-14

A Study of TQ-B3525 Tablets Combined With Fulvestrant Injection in Subjects With HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer

Start: 2020-07-31End: 2021-09-30Target: 42Updated: 2020-04-21

Material Balance Study of TQ-B3525

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Chronic Kidney Diseases, Magnetic Resonance Imaging

Start: 2023-01-31End: 2023-12-31Target: 8Updated: 2023-01-12

Phase 2

A Study of TQ-B3525 in the Treatment of Relapsed / Refractory Follicular Lymphoma (FL)

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Relapsed / Refractory Follicular Lymphoma

Start: 2020-05-20End: 2022-12-31Target: 80Updated: 2020-07-01

A Study of TQ-B3525 Tablet in the Treatment of Relapsed / Refractory Mantle Cell Lymphoma (MCL)

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Relapsed / Refractory Mantle Cell Lymphoma (MCL)

Start: 2020-07-20End: 2021-09-30Target: 102Updated: 2020-09-11

A Study of TQ-B3525 in Subjects With Relapsed/Refractory Peripheral T-cell Lymphoma（PTCL）

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Peripheral T-cell Lymphoma

Start: 2020-12-01End: 2022-10-31Target: 78Updated: 2020-11-04

Related Papers

A novel and selective oral PI3Kα/δ inhibitor, TQ-B3525, in patients with relapsed and/or refractory follicular lymphoma: A phase II, single-arm, open-label study.

Journal of Clinical Oncology2024-06-01

Phase II study of novel orally PI3Kα/δ inhibitor TQ-B3525 in relapsed and/or refractory follicular lymphoma.

2024-04-178 citations

Safety and efficacy of TQ-B3525, a novel and selective oral PI3K α/δ inhibitor, in Chinese patients with advanced malignancies: A phase I dose-escalation and expansion trial.

Journal of Clinical Oncology2020-05-209 citations